Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
about
Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinomaHepatitis C virus infection and type 1 and type 2 diabetes mellitusCytokinome profile evaluation in patients with hepatitis C virus infectionCytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infectionAPASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysisThe role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.Significance of vitamin d receptor gene polymorphisms for risk of hepatocellular carcinoma in chronic hepatitis C.Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures.Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C.The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapyHepatocellular Carcinoma in a non-Cirrhotic Liver of a HCV-Positive Woman with Sustained Viral ResponseImpact of hepatitis C virus eradication on hepatocellular carcinogenesis.Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development.Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis.Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C.Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy.Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy.Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver DiseasesHepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications.Steatosis and insulin resistance in response to treatment of chronic hepatitis C.Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy.Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye.Reply to antiviral therapy and hepatocellular carcinogenesis.Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation-wide cohort study.Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C.SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS.Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes.Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C.Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C.Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy.
P2860
Q26766707-744B7F28-32D6-4655-9A28-4D0E38C7B3B5Q26829202-F03F5AA6-3E8A-47EE-B62E-A35B19DC3B22Q26849696-A3F51B29-A3DB-495D-A24F-C8F64FA23788Q28480545-80C3D705-DE77-4CE6-9479-F23DC2929770Q30250088-583BEDD1-E917-4EBA-9FA4-3BAC1BA9BD11Q33646525-916F84A2-16C1-4438-97E8-5FB83AFE6149Q34113485-334BD979-149F-48AF-8465-E540D83C44CFQ34369199-4E57FDCD-CB10-4250-A4D9-89E42C817FE2Q34497272-F562C8FE-AD36-43CB-BD12-8FA3E8F1961DQ34628015-5A8D1B57-611C-4C7D-8B58-3B2FDFBA5AF9Q35135141-F6826167-A625-4748-819F-7D36FB2CFC4CQ35560273-F5BF4423-8B09-4F9A-BE9A-F380DD61B655Q35985401-CB06DE3D-DEDC-40AF-AB9F-0547D96650FDQ36329125-660DEF34-D9A7-4BA4-B872-081CC1201D35Q36334385-3BDA9355-0DE3-472C-8138-C146F19DA103Q36611684-C70650B9-ABF6-482C-946E-E149D3E5EB90Q37158382-DA6BB2E3-AA3D-48D8-BD67-2EFF0457E35AQ37279232-5C07D9D5-1B1B-44E2-AF9E-56F7B88D45A1Q37328172-692B7C0F-B3ED-4EA5-92F9-CBCEE63467CDQ37685491-59D3CF87-B5CD-4D77-B7FB-1CE7E2DBCF08Q37703437-D8A84D65-FFAC-429B-8114-781F9B5D6B15Q37879191-1D2FE868-C9F7-4E3D-9784-24C2FE19A95DQ37974700-711D56AB-8B9A-4D00-BD99-38EAD2D7980DQ38232812-1B543265-0BA5-4C43-941B-83EE6D955189Q38522791-E10BBAB8-597B-4BA1-B94C-EFCFB911E7B7Q38945243-3BCE9C13-431D-4F1D-ABE1-BA43D00BD683Q39039478-36791846-43B2-4C70-8A29-452C877D05F3Q40695544-9C718252-D129-4723-BAD5-7640D163A3B6Q40722730-3399DE6D-E98A-429F-A331-C65645CAC762Q40873258-D2CEEE52-6FD5-414B-906F-C2D85052642CQ41535486-A1BAE543-E571-46BB-94E6-C45B64804856Q41928201-C766AD38-EE88-49EC-85DF-C6AC5399C036Q42250363-162AE2B5-677B-44B8-8AA3-0E6C74455CD9Q48106729-612290DC-C7BF-46FB-9390-A9BE06D1ADD6Q51761924-48B7F738-B3B6-4DEE-9B8F-DF66C2DFC58DQ54944680-7724CC65-CBEB-4F69-AEA6-E5305B9517A6
P2860
Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Impact of diabetes mellitus on ...... feron-based antiviral therapy.
@en
Impact of diabetes mellitus on ...... feron-based antiviral therapy.
@nl
type
label
Impact of diabetes mellitus on ...... feron-based antiviral therapy.
@en
Impact of diabetes mellitus on ...... feron-based antiviral therapy.
@nl
prefLabel
Impact of diabetes mellitus on ...... feron-based antiviral therapy.
@en
Impact of diabetes mellitus on ...... feron-based antiviral therapy.
@nl
P2093
P2860
P356
P1476
Impact of diabetes mellitus on ...... feron-based antiviral therapy.
@en
P2093
Chao-Hung Hung
Chien-Hung Chen
Chih-Yun Lin
Chuan-Mo Lee
Jing-Houng Wang
Sheng-Nan Lu
Tsung-Hui Hu
P2860
P304
P356
10.1002/IJC.25585
P577
2011-05-01T00:00:00Z